Advanced search
Publication Cover
Cancer Investigation Volume 27, 2009 - Issue 9
Submit an article Journal homepage
81
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

A. R. Jazieh
, MD, MPH,
R. KomrokjiUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD,
A. GuptaUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD,
S. PatilUniversity of Memphis, Memphis, Tennessee, USA.
, MD,
D. FloraOncology Hematology Oncology Care, Cincinnati, Ohio, USA.
, MD,
M. KnappMid Ohio Hematology Oncology, Columbus, Ohio, USA.
, MD,
M. IssaKing Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
, MSc &
N. Abdel KarimUniversity of Cincinnati, Cincinnati, Ohio, USA.
, MD show all
Pages 932-936 | Published online: 15 Oct 2009

REFERENCES

  • Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57, 43–66.
  • Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regiments for advanced non-small cell lung cancer. N Engl J Med 2002, 346, 92–8.
  • Dragnev, K.H.; Rigas, J.R. The future beyond platinum for the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999, 26, 73–6.
  • Bengtson, E.M.; Rigas, J.R. A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum. Semin Oncol. 1999, 26, 1–6.
  • Comis, R.L.; Finley, R.S. Future directions in the treatment of non-small cell lung cancer. Semin Oncol. 1999, 26, 14–8.
  • Kawahara, M.; Kris, M.G.; Green, M.; Kunitoh, H. New drug and multimodality combinations in the treatment of advanced non-small cell lung cancer. Semin Oncol. 2001, 28, 1–4.
  • Rocha Lima, C.M.; Eckardt, J.R.; Leong, S.S.; Sherman, C.A.; Perkel, J.A.; Putman, T.; Safa, A.R.; Bahadori, H.R.; Green, M.R. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999, 26, 43–50.
  • Ferrigno, D.; Buccheri, G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer. 2000, 29, (2), 91–104.
  • Lynch, T.J. Jr. Lung cancer highlights. Oncologist. 2000, 5(4), 274–9.
  • Rocha Lima, C.M.; Urbanic, J.J.; Lal, A.; Kneuper-Hall, R.; Brunson, C.Y.; Green, M.R. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol. 2001, 28, 34–43.
  • Lilenbaum, R.; Socinski, M.A.; Altorki, N.K.; Hart, L.L.; Keresztes, R.S.; Hariharan, S.; Morrison, M.E.; Fayyad, R.; Bonomi, P. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small cell lung cancer. J Clin Oncol. 2006, 24(30), 4825–32.
  • DeCicco, K.L.; Tanaka, T.; Andreola, F.; De Luca L.M.; The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. Carcinogenesis. 2004, 25(10), 1805–12.
  • Sridhar, S.S.; Shepherd FA Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. 2003, 42, S81–91.
  • Gelati, M.; Corsini, E.; Frigerio, S.; Pollo, B.; Broggi, G.; Croci, D.; Silvani, A.; Boiardi, A.; Salmaggi, A. Effects of the thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol. 2003, 64(3), 193–201.
  • Du, G.; Lin, H.H.; XU, QT.; Wang, M.W. Thalidomide inhibits growth of tumors thorugh COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005, 43(2), 112–9.
  • Merchant, J.J.; Kim, K.; Mehta, M.P.; Ripple, G.H.; Larson, M.L.; Brophy, D.J.; Hammes, L.C.; Schiller, J.H.; Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer. Clin Lunc Cancer. 2000, 2(1), 48–52.
  • Kaplan, E.L.; Meier, P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958, 53, 457–481.
  • Govindarajan, R.; Heaton, K.M.; Broadwater, R.; Zeitin, A.; Lang, N.P.; Hauer-Jensen, M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000, 356, 566–7.
  • Govindarajan, R. Irinotecan and thalidomide in metastatic colorectal cancer. Oncology. 2000, 14, 29–32.
  • Allegrini, G.; Di Paolo, A.; Cerri, E.; Cupini, S.; Amatori, F.; Masi, G.; Danesi, R.; Marcucci, L.; Bocci, G.; Del Tacca, M.; Falcone, A. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. Cancer Chemother Pharmacol. 2006, 58(5), 585–593.
  • Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; Herbst, R.S.; Nemunaitis, J.J.; Jablons, D.M.; Langer, C.J.; DeVore, R.F. 3rd; Gaudreault, J.; Damico, LA; Holmgren, E.; Kabbinavar, F. randomized phase II trial comparing Bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2004, 22(11), 2184–91.
  • Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, JH; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with Bevacizumab for non-small cell lung cancer. N Engl J Med. 2006, 355(24), 2542–50.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.